MedTrace Logo

The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection

NCT04636034 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2022-06-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of the ganglion sphenopalatine block (SPG block) on persistent headache following acute COVID-19 infection.

Conditions

  • Headache
  • Covid19
  • Sphenopalatine Ganglion Block
  • Persistent Headache Following COVID-19

Interventions

PROCEDURE

Sphenopalatine Ganglion Block with Local Anesthetic

Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL

PROCEDURE

Sphenopalatine Ganglion Block with Placebo (Isotone NaCl)

Block performed with bilaterally inserted q-tips with isotone NaCl

PROCEDURE

"Sham"-block with Placebo (Isotone NaCl)

Block performed with bilaterally inserted q-tips with isotone NaCl. The q-tips are inserted a maximum of 3 cm into the nasopharynx thus not reaching the mucus above the ganglion.

Sponsors & Collaborators

  • University Hospital Bispebjerg and Frederiksberg

    lead OTHER

Principal Investigators

  • Christian S Meyhoff, PhD · University Hospital Bispebjerg and Frederiksberg

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2022-06-06
Completion
2022-06-06

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04636034 on ClinicalTrials.gov